title: [Long-term outcome of type V lupus membranous glomerulonephritis].
abstract: BACKGROUND
  The long-term outcome of the pure form of WHO type V lupus membranous glomerulonephritis is apparently more benign than that of other forms of lupus glomerulonephritis. However 12% of such patients progress to terminal renal failure. The presence of proteinuria may be an indication of cytotoxic agents.
  
  
  OBJECTIVE
  To study the clinical long-term outcome of WHO type V lupus membranous glomerulonephritis.
  
  
  METHODS
  A retrospective analysis of all kidney biopsies of a University Pathology Department, with the diagnosis of WHO type V lupus membranous glomerulonephritis. Review of medical records of patients with the disease and one clinical assessment of all living patients.
  
  
  RESULTS
  Between 1973 and 2000, 703 kidney biopsies were done to patients with systemic lupus erythematosus. Of these, 40 were membranous glomerulonephritis and in 33 patients (28 women, age range 6-71 years), data on the evolution and survival was obtained. Nineteen had type Va and the rest type Vb nephritis. Two presented with renal failure and 11 with proteinuria over 3.5 g/24 h. The median follow-up since the renal biopsy was 63 months (range 1-316). At the end of follow-up, four had a creatinine clearance of less then 15 ml/h and four a clearance between 15 and 29 ml/h (one of these received a renal allograft). Eleven (33%) patients had died, mostly due to infections. Life expectancy at five years with a creatinine clearance over 15 ml/h was 75%. Bad prognostic factors were an elevated creatinine clearance over 15 ml/h was 75%. Bad prognostic factors were an elevated creatinine and high blood pressure at the moment of the biopsy.
  
  
  CONCLUSIONS
  The clinical outcome of these patients was bad. Twelve percent reached a stage of terminal renal failure. This is in contrast with the 3% progression to a similar stage of proliferative glomerulonephritis treated with i.v. cyclophosphamide. New therapies for this condition must be sought.
authors.affiliation: Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina de la Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Rolando
authors.initials: R
authors.lastname: Pastén V
authors.forename: Loreto
authors.initials: L
authors.lastname: Massardo V
authors.forename: Helmar
authors.initials: H
authors.lastname: Rosenberg G
authors.forename: Francisco
authors.initials: F
authors.lastname: Radrigán A
authors.forename: Emilio
authors.initials: E
authors.lastname: Roessler B
authors.forename: Andrés
authors.initials: A
authors.lastname: Valdivieso D
authors.forename: Sergio
authors.initials: S
authors.lastname: Jacobelli G
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001706:Biopsy; D002648:Child; D002677:Chile / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis